Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of denosumab efficacy, safety, and conversion patterns in cancer patients
ChiCTR2500097786Phase 4Not yet recruiting
- Sponsor
- Zhengzhou People's Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in Giant Cell Tumor of Bone (GCTB), multiple myeloma (MM) and Nonhematologic neoplasms (5 arms), sponsored by Zhengzhou People's Hospital. Primary endpoint: Types, frequency, and time of occurrence of skeletal-related events within 6 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)multiple myeloma (MM)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500097786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097786.